Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary) ; Vilanterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 29 Jun 2017 Planned primary completion date changed from 1 Feb 2018 to 17 Apr 2018.
- 22 Sep 2016 Planned End Date changed from 1 Feb 2018 to 1 Apr 2018.
- 26 Mar 2015 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018, as reported by ClinicalTrials.gov.